Atlas Trials

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Clinical trial NCT06427798 · RECRUITING

Trial details

NCT number
NCT06427798
Sponsor
National Cancer Institute (NCI)
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Somatostatin Receptor PositiveGastrointestinal Neuroendocrine TumorsPheochromocytomaParagangliomas
Start date
2025-02-07
Primary completion
2029-07-01
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.